Literature DB >> 1199816

Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.

I Andersson, A K Granerus, R Jagenburg, A Svanborg.   

Abstract

The intestinal decarboxylation and the absorption of orally administered L-dopa have been studied in 20 parkinsonian patients in different conditions. The decarboxylation generally amounted to 50-70% of the dose given, i.e. only 30-50% of orally administered L-dopa reached the general circulation. The shape of the plasma concentration curve varied individually and with the resolvation time of the type of pharmacological preparation given. No obvious difference in the degree of intestinal decarboxylation was observed when tablets with different resolvation times were given but the net absorption of L-dopa was somewhat greater when it was given as a solution. The decarboxylation in the intestinal organs was found to be rather constant at different times of the day. Isocaloric meals, whether rich in protein or carbohydrate, caused a delay in absorption of L-dopa, but did not change the degree of decarboxylation. Diurnal variations in the clinical response to L-dopa, could, thus, not be related to diurnal variations in the decarboxylation in the intestinal organs. The delay in L-dopa absorption after meals may be misinterpreted as lack of response. At dosage with short intervals, the delay may cause an additive effect of two doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1199816

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  6 in total

1.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.

Authors:  M Murata; H Mizusawa; H Yamanouchi; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 5.  Treatment of Parkinson's disease.

Authors:  M J Aminoff
Journal:  West J Med       Date:  1994-09

Review 6.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.